Jordan J. Feld

27.5k total citations · 4 hit papers
383 papers, 13.7k citations indexed

About

Jordan J. Feld is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Jordan J. Feld has authored 383 papers receiving a total of 13.7k indexed citations (citations by other indexed papers that have themselves been cited), including 331 papers in Hepatology, 311 papers in Epidemiology and 40 papers in Infectious Diseases. Recurrent topics in Jordan J. Feld's work include Hepatitis C virus research (304 papers), Hepatitis B Virus Studies (228 papers) and Liver Disease Diagnosis and Treatment (221 papers). Jordan J. Feld is often cited by papers focused on Hepatitis C virus research (304 papers), Hepatitis B Virus Studies (228 papers) and Liver Disease Diagnosis and Treatment (221 papers). Jordan J. Feld collaborates with scholars based in Canada, United States and Netherlands. Jordan J. Feld's co-authors include Jay H. Hoofnagle, Harry L.A. Janssen, Bettina E. Hansen, Stefan Zeuzem, Michael P. Manns, Jake T. Liang, Jenny Heathcote, E. Jenny Heathcote, Heiner Wedemeyer and Rozanne C. de Veer and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Jordan J. Feld

360 papers receiving 13.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis

2012 1.1k citations Jordan J. Feld, Stefan Zeuzem et al. profile →
Mechanism of action of interferon and ribavirin in treatment of hepatitis C

2005 758 citations Jordan J. Feld et al. profile →
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

2014 686 citations Jordan J. Feld et al. profile →
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores

2019 233 citations Jordan J. Feld et al. profile →

Peers

Countries citing papers authored by Jordan J. Feld

Since Specialization

Citations

This map shows the geographic impact of Jordan J. Feld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jordan J. Feld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jordan J. Feld more than expected).

Fields of papers citing papers by Jordan J. Feld

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jordan J. Feld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jordan J. Feld. The network helps show where Jordan J. Feld may publish in the future.

Co-authorship network of co-authors of Jordan J. Feld

This figure shows the co-authorship network connecting the top 25 collaborators of Jordan J. Feld. A scholar is included among the top collaborators of Jordan J. Feld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jordan J. Feld. Jordan J. Feld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	National hepatitis B and C estimates for 2021: Measuring Canada’s progress towards eliminating viral hepatitis as a public health concern 2025 ·Canada Communicable Disease Report ·(unknown), (unknown), (unknown), John E. Elliott, Fan Zhang, Qiuying Yang, Joseph Cox, (unknown), Jordan J. Feld, Marina B. Klein, Nadine Kronfli, Mia J. Biondi, Peter Daley, (unknown)	0
2	Management of immune-tolerant chronic hepatitis B 2025 ·Hepatology ·(unknown), Milan J. Sonneveld, Jordan J. Feld, Harry L.A. Janssen	0
3	HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER) 2025 ·Gut ·(unknown), (unknown), Seng Gee Lim, Marc Bourlière, (unknown), Nathalie Ganne‐Carrié, Willem Pieter Brouwer, Jordan J. Feld, (unknown), J.A. Carrión, (unknown), (unknown), Scott Fung, Fabrice Carrat, Fabien Zoulim, Bettina E. Hansen, Qing Xie, Harry L.A. Janssen, Milan J. Sonneveld	1
4	Liver-restricted Type I IFN Signature Precedes Liver Damage in Chronic Hepatitis B Patients Stopping Antiviral Therapy 2024 ·The Journal of Immunology ·(unknown), Deeqa Mahamed, Shirin Nkongolo, (unknown), (unknown), David Wong, Raymond T. Chung, Jordan J. Feld, Harry L.A. Janssen, Adam J. Gehring	6
5	Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B 2024 ·Journal of Viral Hepatitis ·Mina Farag, Margo J. H. van Campenhout, Milan J. Sonneveld, Scott Fung, Karel J. van Erpecum, David Wong, Elke Verhey, Robert de Man, Robert J. de Knegt, Johannes T. Brouwer, (unknown), Jordan J. Feld, (unknown), André Boonstra, Bettina E. Hansen, Harry L.A. Janssen	7
6	Early HBcrAg and Anti‐HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials 2024 ·Alimentary Pharmacology & Therapeutics ·(unknown), Jordan J. Feld, André Boonstra, Sylvia M. Brakenhoff, David Wong, Colina Yim, Mark A. A. Claassen, Pieter Honkoop, Bettina E. Hansen, Robert A. de Man, Scott Fung, Thomas Berg, Florian van Bömmel, Harry L.A. Janssen, Milan J. Sonneveld	2
7	What Is Needed to Move Toward Single-Step Diagnosis of Current HCV Infection? 2023 ·The Journal of Infectious Diseases ·Jordan J. Feld	6
8	Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations 2023 ·Clinical Infectious Diseases ·Jordan J. Feld, Julie Bruneau, Gregory J. Dore, Marc G. Ghany, Bettina E. Hansen, Mark Sulkowski, David L. Thomas	6
9	IL-2 produced by HBV-specific T cells as a biomarker of viral control and predictor of response to PD-1 therapy across clinical phases of chronic hepatitis B 2023 ·Hepatology Communications ·(unknown), Loghman Salimzadeh, Ann T., Oyedele Adeyi, (unknown), Giselle M. Boukhaled, (unknown), Anjali Patel, Sara Ferrando‐Martínez, Scott H. Robbins, (unknown), David Wong, Harry L.A. Janssen, David G. Brooks, Jordan J. Feld, Adam J. Gehring	8
10	Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Is It Time to Be Real? 2023 ·Clinical Infectious Diseases ·T. Jake Liang, Jordan J. Feld, Naglaa H. Shoukry, David L. Thomas	1
11	Combined COVID-19 vaccination and hepatitis C virus screening intervention in marginalised populations in Spain 2023 ·SHILAP Revista de lepidopterología ·Jeffrey V. Lazarus, Marcela Villota‐Rivas, Pablo Ryan, Marı́a Buti, Lara Grau‐López, Guillermo Cuevas, (unknown), (unknown), Raúl Felipe Palma-Álvarez, Jordan J. Feld, (unknown)	5
12	HepG2-NTCP Subclones Exhibiting High Susceptibility to Hepatitis B Virus Infection 2022 ·Viruses ·Muhammad Atif Zahoor, (unknown), (unknown), Adam J. Gehring, Jordan J. Feld	3
13	Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension 2022 ·Infectious Diseases and Therapy ·Robert S. Brown, Michelle A. Collins, Simone I. Strasser, Amanda Emmett, (unknown), Margaret Burroughs, (unknown), Jordan J. Feld	1
14	Progress towards hepatitis C virus elimination in high‐income countries: An updated analysis 2021 ·Liver International ·Ivane Gamkrelidze, Jean–Michel Pawlotsky, Jeffrey V. Lazarus, Jordan J. Feld, Stefan Zeuzem, Yanjun Bao, (unknown), Yuri Sánchez González, Homie Razavi	74
15	The emergency department as a setting‐specific opportunity for population‐based hepatitis C screening: An economic evaluation 2020 ·Liver International ·(unknown), David Naimark, William Wong, (unknown), Jordan J. Feld, Wanrudee Isaranuwatchai, Murray Krahn	19
16	The impact of SVR from direct‐acting antiviral‐ and interferon‐based treatments for HCV on hepatocellular carcinoma risk 2020 ·Journal of Viral Hepatitis ·Naveed Z. Janjua, Stanley Wong, Maryam Darvishian, Zahid A Butt, Amanda Yu, Mawuena Binka, Maria Alvarez, Ryan Woods, Eric M. Yoshida, Alnoor Ramji, Jordan J. Feld, Mel Krajden	37
17	Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study 2020 ·Hepatology Communications ·Bertus Eksteen, Christopher L. Bowlus, Aldo J. Montaño‐Loza, Éric Lefebvre, Laurent Fischer, Pamela Vig, Eduardo B. Martins, Jawad Ahmad, Kidist Yimam, Paul J. Pockros, Jordan J. Feld, Gerald Y. Minuk, Cynthia Levy	35
18	The Ubiquitin-Specific Protease 18 Promotes Hepatitis C Virus Production by Increasing Viral Infectivity 2019 ·Mediators of Inflammation ·Yujia Li, (unknown), Bo Qin, Liang Lin, Christopher D. Richardson, Jordan J. Feld, Ian D. McGilvray, Limin Chen	6
19	Efficacy and safety of a two‐drug direct‐acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6 2019 ·Journal of Viral Hepatitis ·Eric Lawitz, Edward Gane, Jordan J. Feld, Marı́a Buti, Graham R. Foster, Mordechai Rabinovitz, (unknown), Helena Katchman, Krzysztof Tomasiewicz, Frederick Lahser, Beth E. Jackson, Melissa Shaughnessy, Stephanie O. Klopfer, Wendy W. Yeh, Michael Robertson, George J. Hanna, Eliav Barr, Heather Platt, (unknown)	9
20	The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. 2008 ·PubMed ·Ponsiano Ocama, Michael Katwere, (unknown), Jordan J. Feld, (unknown), Andrew Kambugu, Elly Katabira, David L. Thomas, Robert Colebunders, Allan Ronald	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact